Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 45Neuroblastoma 16Glioma 16Brain Neoplasms 14Astrocytoma 10Neoplasms 8Rhabdomyosarcoma 7Sarcoma, Ewing 6Recurrence 5Oligodendroglioma 5Medulloblastoma 5Sarcoma 4Osteosarcoma 4Melanoma 4Small Cell Lung Carcinoma 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Lymphoma 3Gliosarcoma 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Rhabdoid Tumor 2Pyloric Stenosis, Hypertrophic 2Ovarian Neoplasms 2Neoplasm Metastasis 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2

Interventions

Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Melanoma × Temozolomide × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡